Esther Natalie Olíva

Author

Azienda ospedaliera "Bianchi-Melacrino-Morelli"ORCID

Also Known As

E N Oliva, E OLIVA, E Oliva, E. N. Oliva, E. OLIVA, E. Oliva, E.N. Oliva, Esther N Oliva, Esther N. Oliva, Esther Natalie Oliva

190

Publications

2.5K

Citations

H-Index

Concepts

All Affiliations

Azienda ospedaliera "Bianchi-Melacrino-Morelli"Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Sapienza University of Rome University of Milan Istituti di Ricovero e Cura a Carattere Scientifico

About

Esther Natalie Olíva is an author at Azienda ospedaliera "Bianchi-Melacrino-Morelli" specializing in medicine, hematology, and health sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	13	665
2	Health Sciences	6	6	189
3	Natural Sciences	1	1	27
4	Public Health	1	1	11
5	Blood Transplantation	1	1	10

Esther Natalie Olíva

Publications

Citations

H-Index

Page 1

	Year	Citations
Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes Matteo Bersanelli, Erica Travaglino, Manja Meggendorfer, Journal of Clinical Oncology	2021	212
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial Esther Natalie Olíva, Caterina Alati, Valeria Santini, The Lancet Haematology Eltrombopag Versus PlaceboThrombosisThrombopoiesisHematological MalignancySuperiority Trial	2017	159
A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS Pierre Fenaux, Valeria Santini, Maria Antonietta Aloe Spiriti, Leukemia	2018	159
Azacitidine for the treatment of patients with acute myeloid leukemia Luca Maurillo, Adriano Venditti, Alessandra Spagnoli, Cancer	2011	144
A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes Uwe Platzbecker, Argiris Symeonidis, Esther Natalie Olíva, Leukemia	2017	126
Paclitaxel and Platinum Chemotherapy for Malignant Mixed Mullerian Tumors of the Ovary Linda Duska, Audrey P. Garrett, Gamal H. Eltabbakh, Gynecologic Oncology Endocrine OncologyTumoral PathologyMedicineGynecologyCancer Treatment	2002	103
Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes Elisabetta Sauta, Marie Robin, Matteo Bersanelli, Journal of Clinical Oncology	2023	98
Hemoglobin level threshold for cardiac remodeling and quality of life in myelodysplastic syndrome Esther Natalie Olíva, Borislav D. Dimitrov, Frank Benedetto, Leukemia Research Heart FailureMyelodysplastic SyndromeBone Marrow FailureCardiovascular DiseaseHematology	2005	84
A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes Jing Fang, Xiaona Liu, Lyndsey Bolanos, Nature Medicine Hematological MalignancyBone Marrow FailureHematologyPathologyMedicine	2016	82
Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial Catherine M. Broome, Vickie McDonald, Yoshitaka Miyakawa, The Lancet ThrombopoiesisAutoimmune DiseaseBlood PlateletPrimary Immune ThrombocytopeniaImmunology	2023	77

Page 1